GlassScriptPhysician profile
Amy C Claunch
NPI 1861943029
$6,778.96
in general payments reported to CMS, 2019-2025
48 companies · $1,134 in 2025
The $1,134 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $828 · 2022: $1,225 · 2023: $1,796 · 2024: $1,797 · 2025: $1,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,681 · Education: $45.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,681.11 |
| Education | $45.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,079.86 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $884.31 | 2021-2025 | |
| Lilly USA, LLC | $617.42 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $512.53 | 2021-2024 | Farxiga |
| Pfizer INC. | $511.60 | 2023-2025 | |
| Glaxosmithkline, LLC. | $422.04 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $313.29 | 2021-2025 | Otezla, Repatha, Evenity |
| Novo Nordisk INC | $278.71 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Horizon Therapeutics Plc | $209.24 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $194.23 | 2023-2025 | Gemtesa |
| Vanda Pharmaceuticals INC. | $138.90 | 2024-2025 | Fanapt |
| Fresenius USA Marketing, INC. | $131.14 | 2021-2022 | |
| Axsome Therapeutics, INC. | $119.78 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $109.24 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.03 | 2022-2024 | Jardiance, Ofev |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Claunch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.